KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $61.1 million.

  • CRISPR Therapeutics AG's Net Cash Flow fell 1597.98% to $61.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $49.2 million, marking a year-over-year increase of 15391.31%. This contributed to the annual value of $49.2 million for FY2025, which is 15391.31% up from last year.
  • CRISPR Therapeutics AG's Net Cash Flow amounted to $61.1 million in Q4 2025, which was down 1597.98% from $92.9 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Net Cash Flow high stood at $521.8 million for Q2 2021, and its period low was -$636.3 million during Q3 2021.
  • Its 5-year average for Net Cash Flow is -$41.3 million, with a median of -$42.1 million in 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Net Cash Flow tumbled by 69546.03% in 2021 and then surged by 324337.62% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Net Cash Flow stood at -$88.5 million in 2021, then crashed by 223.76% to -$286.4 million in 2022, then surged by 51.61% to -$138.6 million in 2023, then surged by 152.44% to $72.7 million in 2024, then dropped by 15.98% to $61.1 million in 2025.
  • Its Net Cash Flow was $61.1 million in Q4 2025, compared to $92.9 million in Q3 2025 and -$41.6 million in Q2 2025.